Genecure Biotechnologies
Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Phase 1
- Conditions
- COVID
- Interventions
- Biological: Covax-19™
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- GeneCure Biotechnologies
- Target Recruit Count
- 32
- Registration Number
- NCT04428073
Therapeutic Hepatitis C Virus Vaccine
Phase 1
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- Biological: HCVax
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- GeneCure Biotechnologies
- Target Recruit Count
- 30
- Registration Number
- NCT04318379
- Locations
- 🇺🇸
Virginia Commonwealth University, Medical Center, Richmond, Virginia, United States
Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects
Phase 1
- Conditions
- HIV Infections
- Interventions
- Biological: HIVAXBiological: saline solution
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- GeneCure Biotechnologies
- Target Recruit Count
- 30
- Registration Number
- NCT01428596
- Locations
- 🇺🇸
University of Miami School of Medicine, AIDS Clinical Research unit, Miami, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath